Synergen Inc. other research news

SYGN told BioCentury that its Phase II/III trial of CNTF in amyotrophic lateral sclerosis (ALS) is using lower doses than those that prompted Regeneron Pharmaceuticals Inc. to halt its development of the drug. REGN last week announced that it was dropping CNTF after concluding that its Phase III trial data did not demonstrate efficacy, due in part to side effects ...